Wegovy (Semaglutide 2.4mg) — Complete Guide 2026
Wegovy is the FDA-approved semaglutide formulation specifically for chronic weight management. Learn about dosing, average weight loss from STEP-1 trial data, real cost, side effects, and how Wegovy compares to Ozempic and Mounjaro.
Results are estimates only — consult your healthcare provider before making medical decisions.
Wegovy at a Glance
What Is Wegovy? FDA-Approved for Weight Management
Wegovy is the brand name for semaglutide 2.4mg, the highest dose of semaglutide approved by the FDA. Unlike Ozempic (approved for diabetes), Wegovy received FDA approval in June 2021 specifically for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity.
FDA eligibility criteria for Wegovy:
- Adults with initial BMI ≥30 kg/m² (obesity), or
- Adults with initial BMI ≥27 kg/m² (overweight) with at least one weight-related comorbidity such as high blood pressure, Type 2 diabetes, or high cholesterol
In December 2023, the SELECT trial demonstrated that semaglutide 2.4mg reduces the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in people with obesity or overweight with established cardiovascular disease. This expanded Wegovy's clinical utility beyond pure weight management.
Wegovy Weight Loss Results: STEP-1 Trial Data
The pivotal STEP-1 trial (Wilding et al., NEJM, 2021) is the gold standard for understanding Wegovy's weight loss potential. 1,961 adults without diabetes participated, randomized to semaglutide 2.4mg or placebo for 68 weeks.
| Weight Loss Level | % of Wegovy Patients Achieving This | % of Placebo Patients Achieving This |
|---|---|---|
| Any weight loss | 97% | 68% |
| At least 5% loss | 83% | 31% |
| At least 10% loss | 67% | 12% |
| At least 15% loss | 50% | 5% |
| At least 20% loss | 33% | 2% |
| Average (mean) loss | 15.3% | 2.6% |
Source: Wilding et al., NEJM 2021. Results for participants who completed 68 weeks of treatment. Individual results vary based on diet, exercise, starting weight, and adherence.
Predict your personal weight loss timeline on Wegovy or any GLP-1 medication:
Try the Weight Loss Calculator →Wegovy Dosing Schedule (2.4mg Titration Protocol)
Wegovy requires a 5-step titration over approximately 16–20 weeks. Novo Nordisk provides separate pens for each dose level. Do not attempt to adjust your pen's dose — each pen delivers a fixed dose.
| Phase | Duration | Dose |
|---|---|---|
| Initiation | Weeks 1–4 | 0.25 mg/week |
| Escalation 1 | Weeks 5–8 | 0.5 mg/week |
| Escalation 2 | Weeks 9–12 | 1.0 mg/week |
| Escalation 3 | Weeks 13–16 | 1.7 mg/week |
| Maintenance | Week 17+ | 2.4 mg/week (maximum) |
Wegovy's titration has an additional step compared to Ozempic (1.7mg before 2.4mg), reflecting the higher target dose. If GI side effects are intolerable, your doctor can keep you at a lower dose for an extra 4 weeks before escalating.
Wegovy Cost in 2026: Insurance, Savings Cards, and Alternatives
| Payment Method | Monthly Cost | Key Notes |
|---|---|---|
| No insurance (retail) | ~$1,300–$1,400 | List price at major US retail pharmacies |
| Commercial insurance | $25–$200 | Coverage for weight management is improving but inconsistent; ~40% of plans as of 2026 |
| Wegovy Savings Card | As low as $25 (first year) | Commercially insured patients; not for Medicare/Medicaid. Program terms change annually. |
| Medicare Part D | Often not covered | Limited coverage for obesity-only indication; covered for CVD patients via SELECT trial indication |
| Compounded semaglutide | $150–$350 | From PCAB-accredited compounding pharmacies; not FDA-approved brand |
Compare all Wegovy cost options with our free calculator:
Use the Cost Calculator →Wegovy Side Effects: What to Expect
Wegovy's side effect profile is similar to Ozempic, but can be more pronounced at the 2.4mg maintenance dose. In STEP-1, approximately 90% of participants experienced at least one GI side effect during the trial, with most being mild to moderate.
- Nausea (44%): Most common. Peaks during dose escalations. Eating protein first, small portions, and avoiding greasy foods significantly helps.
- Diarrhea (30%): More common with Wegovy than lower-dose semaglutide. Usually self-resolving.
- Vomiting (24%): Contact your doctor if severe or persistent — dose escalation may need to slow.
- Constipation (24%): Increase fiber intake gradually; stay well-hydrated.
- Headache (14%): Often related to reduced calorie intake; adequate hydration and electrolytes help.
- Fatigue (11%): Common in early treatment. Ensure adequate protein, sleep, and electrolyte intake.
Wegovy carries the same black box warning as all GLP-1 medications: risk of medullary thyroid carcinoma. It is contraindicated in patients with personal or family history of MTC or MEN2.
Protein Needs on Wegovy: Why They're Higher Than You Think
Because Wegovy produces greater calorie restriction than Ozempic (due to the higher 2.4mg dose), the risk of muscle loss is also somewhat higher without adequate protein intake. The Obesity Medicine Association recommends 1.2–1.6 g of protein per kg body weight daily for all GLP-1 users.
For a 200-lb (91 kg) person on Wegovy, that means 109–145 grams of protein daily. Most Americans consuming a standard diet get 60–80 grams per day — significantly below the GLP-1 user target.
Get your personalized protein target for Wegovy therapy:
Calculate Your Protein Needs →Frequently Asked Questions About Wegovy
Is Wegovy better than Ozempic for weight loss?
Wegovy's 2.4mg maximum dose provides slightly more weight loss than Ozempic's 2.0mg maximum. In STEP-1, Wegovy produced 15.3% average weight loss. Both are semaglutide; the higher dose is the key difference. For pure weight loss without diabetes, Wegovy is the FDA-appropriate choice.
How long does Wegovy take to start working?
Reduced appetite typically begins in the first 1–2 weeks even at the initial 0.25mg dose. Significant weight loss on the scale usually becomes apparent in months 2–4 as the dose escalates. Full therapeutic effect is reached around months 9–12 at the 2.4mg maintenance dose.
Can you take Wegovy if you don't have obesity?
Wegovy is FDA-approved for adults with BMI ≥30 (obesity) or BMI ≥27 (overweight) with a weight-related condition. It is not approved for general weight loss in people with normal BMI. Prescribing it in this population would be off-label use.
What happens after you stop taking Wegovy?
Weight regain is common after stopping Wegovy. The STEP-4 withdrawal trial showed participants regained approximately two-thirds of their lost weight within one year of stopping. Continued treatment is generally recommended to maintain results.
Does Wegovy have a generic version?
No. As of 2026, there is no FDA-approved generic semaglutide. Novo Nordisk's patents on semaglutide run through the mid-2030s. Compounded semaglutide from licensed pharmacies is available and cheaper, but is not an FDA-approved generic equivalent.